Gene therapy long-term follow-up for Krystal Biotech patients
Part of Genetic & congenital, Skin clinical trials.
This study follows people who previously received a gene therapy from Krystal Biotech to better understand long-term safety and outcomes. If you already had their gene therapy before and you can keep follow-up appointments, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one Krystal Biotech gene therapy treatment in an earlier study
- You must have already finished the original study treatment plan (or stopped it) and had long-term follow-up not built in
- You (and a parent/guardian if needed) must agree to the study before any study information is collected
- You must be willing and able to follow the follow-up schedule and study rules
- You must not join from a different company’s gene therapy treatment trial at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients who have already received a gene therapy treatment called prademagene zamikeracel for a severe skin condition called recessive dystrophic epidermolysis bullosa (RDEB). The goal is to track long-term safety and health outcomes after treatment.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
This study checks on people long after they received a gene-modified cell infusion in a Kite-sponsored study. It helps researchers understand how treatments work over time and watch for any long-term effects.
This study checks your health over time after you previously received gene-modified cell therapy in a Sorrento-sponsored trial. It helps researchers understand long-term safety and outcomes and may lead to better care for future patients.
This study is a follow-up check for people who were previously enrolled in certain NCI gene therapy treatment studies. It helps the research team monitor long-term effects and outcomes after treatment.
Hear when a new Dystrophic Epidermolysis Bullosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.